A Phase 1, Open-label, Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Subjects With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy
Latest Information Update: 24 Nov 2022
At a glance
- Drugs Daratumumab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Pharmacokinetics
- Acronyms MMY1003
- Sponsors Janssen Research & Development
- 01 Dec 2022 Results published in the Annals of Hematology
- 23 Jan 2020 Status changed from active, no longer recruiting to completed.
- 05 Dec 2019 Planned End Date changed from 13 Jan 2020 to 31 Jan 2022.